echo "datum här"; Archive | Isofol

Archive

  • Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer

    Isofol Announces Management Team Evolution with Appointment of Dr. Roger Tell as Chief Medical Officer GOTHENBURG, Sweden, August 15, 2019…

    by
  • Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin

    Isofol Announces Recent Advisory Board Meeting Covering Development Plan for arfolitixorin GOTHENBURG, Sweden, July 15, 2019 – Isofol Medical AB…

    by
  • Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin

    Isofol Receives Clinical Use Patent Approval in the United States for Drug Candidate arfolitixorin GOTHENBURG, Sweden, June 25, 2019 –…

    by
  • Isofol Announces Election of Three New Board Members

    Isofol Announces Election of Three New Board Members GOTHENBURG, Sweden, June 10, 2019 – Isofol Medical AB (publ) (Nasdaq First…

    by
  • Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

    Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical…

    by
  • Isofol Reports 58 % Overall Response Rate

    Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study…

    by
  • Poadcast – “The Cancer Gene”

    Listen to recent episode from The Cancer Gene podcast features Anders Rabbe, CEO of Isofol, discussing colorectal cancer and the…

    by
  • aside

    Isofol Reports All Employees Participate in Newly Created Share Warrant Program

    GOTHENBURG, Sweden, February 1, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that all senior…

    by
  • aside

    Isofol has participated in the Empowered Patient Podcast

    In honor of World Cancer Day on February 4, we would like to share a podcast where Anders Rabbe, CEO…

    by
  • aside

    Isofol Reports Early Tumor Shrinkage in Patients with Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    GOTHENBURG, Sweden, January 17, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from…

    by
  • aside

    First patient enrolled in Isofol’s Pivotal Phase 3 AGENT study in 1st line metastatic colorectal cancer

    GOTHENBURG, Sweden, December 18, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced that the first…

    by
  • aside

    Isofol Strengthens Executive Management Team with the Appointment of Roger Tell, MD, PhD, as Chief Scientific Officer and Senior Vice President of Clinical Development

    GOTHENBURG, Sweden, November 19, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the recruitment of…

    by
  • aside

    Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors

    GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of…

    by
  • aside

    Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer

    GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL) today announced initiation of the…

    by
  • aside

    Isofol presents a poster at ESMO 2018 Congress in Germany

    Isofol is attending the ESMO 2018 Congress in Germany, which is taking place between October 19-23. During Sunday the poster, “ISO-CC-005;…

    by
  • aside

    New Chairman and extended board at Isofol Medical AB (publ)

    Isofol Medical AB (publ), developing arfolitixorin as treatment for advanced colorectal cancer is calling an Extraordinary General Meeting on Wednesday…

    by